Effectiveness and tolerability of tomoxetine in adults with attention deficit hyperactivity disorder.
about
Psychostimulants as cognitive enhancers: the prefrontal cortex, catecholamines, and attention-deficit/hyperactivity disorderTreatment of adults with attention-deficit/hyperactivity disorderTreatment of adults with attention-deficit/hyperactivity disorderEfficacy of atomoxetine in adult attention-deficit/hyperactivity disorder: a drug-placebo response curve analysis.Color naming deficits and attention-deficit/hyperactivity disorder: a retinal dopaminergic hypothesis.A critical appraisal of atomoxetine in the management of ADHDEfficacy and tolerability of pharmacotherapies for attention-deficit hyperactivity disorder in adultsDo adrenergically active drugs have a role in the first-line treatment of attention-deficit/hyperactivity disorder?Attention-deficit/hyperactivity disorder in adults: evidence-based recommendations for managementAtomoxetine modulates spontaneous and sensory-evoked discharge of locus coeruleus noradrenergic neurons.The use of antidepressants to treat attention deficit hyperactivity disorder in adults.Lobeline Effects on Cognitive Performance in Adult ADHD.Reboxetine for ADHD in children non-responders or with poor tolerance to methylphenidate: a prospective long-term open-label study.Adult attention deficit hyperactivity disorder.An update on the pharmacotherapy of attention-deficit/hyperactivity disorder in adultsPharmacological characterization of the norepinephrine and dopamine reuptake inhibitor EB-1020: implications for treatment of attention-deficit hyperactivity disorder.Evaluation of the reinforcing effects of monoamine reuptake inhibitors under a concurrent schedule of food and i.v. drug delivery in rhesus monkeys.Attention deficit hyperactivity disorder (ADHD) and substance use disorders.A placebo-controlled trial of atomoxetine in marijuana-dependent individuals with attention deficit hyperactivity disorderNew developments in psychopharmacology of attention deficit hyperactivity disorder.Efficacy of atomoxetine in adults with attention deficit hyperactivity disorder: an integrated analysis of the complete database of multicenter placebo-controlled trials.The search for new off-label indications for antidepressant, antianxiety, antipsychotic and anticonvulsant drugs.Comparative benefits and harms of competing medications for adults with attention-deficit hyperactivity disorder: a systematic review and indirect comparison meta-analysis.A randomized controlled trial investigation of a non-stimulant in attention deficit hyperactivity disorder (ACTION): rationale and design.Differential impact of methylphenidate and atomoxetine on sustained attention in youth with attention-deficit/hyperactivity disorder.Assessment and management of attention-deficit hyperactivity disorder in adults.Structure and diagnosis of adult attention-deficit/hyperactivity disorder: analysis of expanded symptom criteria from the Adult ADHD Clinical Diagnostic ScaleNew approaches to developing antidepressants by enhancing monoaminergic neurotransmission.Atomoxetine treatment of attention-deficit/hyperactivity disorder.A new paradigm for developing drugs in children: atomoxetine as a model.Atomoxetine: a new pharmacotherapeutic approach in the management of attention deficit/hyperactivity disorderReview of new compounds available in Australia for the treatment of attention-deficit hyperactivity disorder.Validity of the World Health Organization Adult ADHD Self-Report Scale (ASRS) Screener in a representative sample of health plan membersAdult ADHD and substance abuse: diagnostic and treatment issues.A review of the abuse potential assessment of atomoxetine: a nonstimulant medication for attention-deficit/hyperactivity disorderPerformance on a strategy set shifting task during adolescence in a genetic model of attention deficit/hyperactivity disorder: methylphenidate vs. atomoxetine treatmentsBupropion SR in adults with ADHD: a short-term, placebo-controlled trial.Substance use disorders in children and adolescents with attention-deficit/hyperactivity disorder: implications for treatment and the role of the primary care physician.Treatment of adult ADHD: is current knowledge useful to clinicians?ADHD in adults: a review of the literature.
P2860
Q22252504-83F85BFE-1A85-4F0D-888F-F200E97E349EQ24642937-F2E7D949-C538-4EA7-B8CA-55C947BAC83EQ24644586-27E3C832-33B2-4F2D-9D1B-D2887199FD88Q24814791-E0E03FD4-9796-4064-BE78-73B016A48029Q25255003-D45F1FE0-AD32-430D-B16F-E3D6BAC6C892Q26771187-D76B19B9-A0EB-4D49-9326-1ECA3150AC09Q28246506-8A251915-6B92-4293-B709-D0222A29BB62Q28274915-408A5029-22D7-4801-9094-E5E54319383CQ28295525-8331275F-A386-4770-AA94-AF836B47595AQ30445190-BF5FC3AE-9B0D-40BC-BDF0-E6536CD777E2Q30482547-447FEBE2-9BD2-43DB-B5A5-0EBA4984FF9FQ33774323-0381B851-E5F6-4B25-B48F-9271C4122649Q34172933-902524BE-30C7-4965-942B-3784E0B783BEQ34200066-9B78959E-6258-4197-A388-07C896CB9E78Q34220004-FF34F0C7-D27D-4C87-94D2-7C2C761EF436Q34251275-CAF86087-72CA-4B6D-86BC-7D134ACA3C59Q34365132-B9168EBC-82AD-44E3-8099-926CD696F889Q34438018-A264A55C-DD5C-4D60-9BA0-7FC610358609Q34481402-2D5250FA-71D4-4F10-A547-0EBCE125E717Q34481761-AC76007F-6A19-4772-B5B7-AB8851901BE9Q34505285-2A138F5E-41EB-4551-B758-C49050223209Q34525841-D0A878CA-02CF-4511-A0B6-91AC8B7A4F86Q34715649-2E06308E-0AAE-40AF-BAD3-674FD4589504Q34743710-DA76CD09-6968-4FF6-B617-D7A18F3BA1E2Q34744662-6117F0A4-A4E8-487C-AB7D-1BE8332DCBF0Q34995011-4BB16E24-5680-4D95-8A93-51EE6478DEEDQ35092195-83653221-5E50-43B3-B8AE-0FB894079CA7Q35094650-38261F74-1C0D-4A89-A672-4C0623724923Q35638049-DC0007EE-8CD7-4E7A-AF09-82E5A179A2BBQ36017525-50A6CC4F-4080-4372-AB72-6F0DFF93E57AQ36017534-8687542F-9334-42E7-8945-136AF88C5530Q36044681-CBDABD30-A176-4692-B408-8A860F2D0FF1Q36097188-FAB98F9F-BF7D-48D8-8F88-A7E0ED3B2669Q36311022-94AF8971-D5AC-41CB-8AFA-CC365DC128D8Q36630601-E45E2B54-42A2-479B-A408-E9EFDBB725B7Q36681100-DA3A07A7-BDAD-40BF-8DE3-3CDC919435DEQ36703814-405120FC-A176-4773-870A-4708A76F1332Q36746621-D29EF044-D47A-40FF-8278-20D41D659ED4Q36836781-A04C7175-996B-46F3-8939-E183DE5FE67DQ37038168-8D4137BF-0CC1-45DD-B3EC-FF5582821DA0
P2860
Effectiveness and tolerability of tomoxetine in adults with attention deficit hyperactivity disorder.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
1998年论文
@zh
1998年论文
@zh-cn
name
Effectiveness and tolerability ...... eficit hyperactivity disorder.
@en
type
label
Effectiveness and tolerability ...... eficit hyperactivity disorder.
@en
prefLabel
Effectiveness and tolerability ...... eficit hyperactivity disorder.
@en
P2093
P356
P1476
Effectiveness and tolerability ...... eficit hyperactivity disorder.
@en
P2093
Faraone SV
P304
P356
10.1176/AJP.155.5.693
P407
P50
P577
1998-05-01T00:00:00Z